At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 53 enrolled
Drug / intervention
AMG 334 Dose 1 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Randomized, Open-label, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine
In Brief
A Phase 1 clinical trial evaluating AMG 334 Dose 1, AMG 334 Dose 2, and 1 other intervention for Migraine. Completed, enrolled 53 participants across 14 sites.
Detailed Summary
AMG 334 20160172 Pediatric Migraine PK Study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartMay 2018
Primary CompletionNov 2021
TodayJul 2026
First PostedApr 17, 2018
Enrollment StartMay 4, 2018
Primary CompletionNov 23, 2021
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 8.2 years ago
Interventions
AMG 334 Dose 1drug
Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3. Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2
AMG 334 Dose 2drug
Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2.
AMG 334 Dose 3drug
Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.